期刊
STROKE
卷 43, 期 2, 页码 539-542出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.111.632026
关键词
acute stroke; magnetic resonance imaging; thrombolysis
资金
- Federal Ministry of Education and Research via from the Center for Stroke Research Berlin [01 EO 0801]
- Volkswagen Foundation
- EU (EuStroke, ARISE)
- German Research Foundation [SFB-TR 43]
- Astra Zeneca
- Bayer
- Berlin Chemie
- BMS
- Boehringer-Ingelheim
- Glaxo Smith Kline
- Novartis
- Pfizer
- Sanofi-Aventis
- Trommsdorff
Background and Purpose-We investigated if hyperintensities on fluid-attenuated inversion recovery (FLAIR) sequences in arteries and parenchyma are associated with poor outcome 3 months after thrombolysis. Methods-Consecutive acute stroke patients with known time of symptom onset who had an MRI before and 1 day after thrombolysis were included in this study. Blinded to follow-up imaging and outcome, 2 raters independently judged the presence or absence of arterial and parenchymal FLAIR hyperintensities. Functional outcome (modified Rankin Scale) was assessed after 3 months. Results-Out of 90 patients, 22 had parenchymal FLAIR hyperintensities and 42 had hyperintense vessels. The combination of FLAIR hyperintensities in arteries and parenchyma occurred in 15 patients. Stepwise forward regression analysis revealed an adjusted odds ratio of 14.5 for a worse outcome (modified Rankin Scale score >2) in patients with FLAIR hyperintensities in arteries and parenchyma (95% confidence interval, 1.3-158.5; P=0.03). Conclusions-FLAIR hyperintensities in arteries and parenchyma are an easy-to-use MRI feature in acute ischemic stroke associated with poor outcome 3 months after thrombolysis. (Stroke. 2012;43:539-542.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据